One of this year’s biggest loss-of-exclusivity opportunities for the US off-patent industry has come to pass, after the US Food and Drug Administration approved more than a dozen generic rivals to Takeda’s blockbuster attention-deficit/hyperactivity disorder treatment Vyvanse (lisdexamfetamine).
Generic versions of lisdexamfetamine capsules in 10mg, 20mg, 30mg 40mg, 50mg, 60mg and 70mg strengths have been approved by the...



